BMS buys rights to PRM-151 and Promedior

August 31, 2015 

Bristol-Myers Squibb has bought rights to a fibrosis drug and its privately held developer - Promedior.  The deal gives Bristol-Myers access to Promedior Inc's lead experimental drug, PRM-151, which is being tested in myelofibrosis as well as diopathic pulmonary fibrosis.

Promedior's mid-stage studies of its fibrosis drug are expected to begin in the next few weeks, Bristol-Myers said on Monday.

Click here for the full release.

Receive updates on the latest MPN news & events.

Find out ways you can help support MPN patients and researchers.

x

NEVER MISS AN UPDATE

Get free, timely information on living with an MPN.

Subscribe